Cheng et al. evaluated TERT-p mutations in SCCs from different anatomic sites, finding a mutation rate of 70% for both skin and urinary bladder SCCs, but only 20% for head and neck SCC, and no TERT-p mutations were identified in uterine cervix and lung cancer (Cheng et al. 2015). This evidence concerns the gene TERT and lung carcinoma.